Antipsychotics increase vesicular glutamate transporter 2 (VGLUT2) expression in thalamolimbic pathways

Neuropharmacology

Volumn 54, Issue 3, 2008, Pages 497-508

  Moutsimilli, Larissa ^a   Farley, Severine ^a   El Khoury, Marie Anne ^a   Chamot, Christophe ^b   Sibarita, Jean Baptiste ^c   Racine, Victor ^d   El Mestikawy, Salah ^a   Mathieu, Flavie ^a   Dumas, Sylvie ^e   Giros, Bruno ^a   Tzavara, Eleni T ^a  

^a INSERM   (France)

^b CNRS   (France)

^c INSTITUT CURIE   (France)

^d INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^e Helios Biosciences   (France)

Author keywords

Amphetamine; Antidepressants; Antipsychotics; Diazepam; Glutamate; Limbic; Lithium; Thalamus; Vesicular transporter

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; DESIPRAMINE; DIAZEPAM; FLUOXETINE; HALOPERIDOL; LITHIUM; MESSENGER RNA; MOOD STABILIZER; NEUROLEPTIC AGENT; RISPERIDONE; VESICULAR GLUTAMATE TRANSPORTER 2;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; MALE; MOUSE; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; THALAMOCORTICAL TRACT; THALAMUS MIDLINE NUCLEUS; THALAMUS NUCLEUS; THALAMUS PARAFASCICULAR NUCLEUS;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; GENE EXPRESSION REGULATION; LIMBIC SYSTEM; MALE; MICE; MICE, INBRED C57BL; NEURAL PATHWAYS; RNA, MESSENGER; THALAMUS; VESICULAR GLUTAMATE TRANSPORT PROTEIN 2;

EID: 38749095177     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.10.022     Document Type: Article

References (44)

1. Aihara Y., Mashima H., Onda H., Hisano S., Kasuya H., Hori T., Yamada S., Tomura H., Yamada Y., Inoue I., Kojima I., and Takeda J. Molecular cloning of a novel brain-type Na(C)-dependent inorganic phosphate cotransporter. Journal of Neurochemistry 74 (2000) 2622-2655
2. Berendse H.W., and Groenewegen H.J. Organization of the thalamostriatal projections in the rat, with special emphasis on the ventral striatum. Journal of Comparative Neurology 299 (1990) 187-228
3. Berendse H.W., and Groenewegen H.J. Restricted cortical termination fields of the midline and intralaminar thalamic nuclei in the rat. Neuroscience 42 (1991) 73-102
4. Cardinal R.N., Parkinson J.A., Hall J., and Everitt B.J. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neuroscience Biobehavioral Reviews 26 (2002) 321-352
5. Centonze D., Usiello A., Costa C., Picconi B., Erbs E., Bernardi G., Borrelli E., and Calabresi P. Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors. Journal of Neuroscience 24 (2004) 8214-8222
6. Christakou A., Robbins T.W., and Everitt B.J. Prefrontal cortical-ventral striatal interactions involved in affective modulation of attentional performance: implications for corticostriatal circuit function. Journal of Neuroscience 24 (2004) 773-780
7. Cohen B.M., and Yurgelun-Todd D. Alterations of thalamic activity in schizophrenia and in response to antipsychotic drugs: studies in the legacy of Seymour S. Kety. Neuropsychopharmacology 25 (2001) 305-312
8. Cohen B.M., Wan W., Froimowitz M.P., Ennulat D.J., Cherkerzian S., and Konieczna H. Activation of midline thalamic nuclei by antipsychotic drugs. Psychopharmacology (Berl) 135 (1998) 37-43
9. Daniels R.W., Collins C.A., Gelfand M.V., Dant J., Brooks E.S., Krantz D.E., and DiAntonio A. Increased expression of the Drosophila vesicular glutamate transporter leads to excess glutamate release and a compensatory decrease in quantal content. Journal of Neuroscience 24 (2004) 10466-10474
10. Deutch A.Y., Ongur D., and Duman R.S. Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: a novel locus of antipsychotic drug action. Neuroscience 66 (1995) 337-346
11. Fremeau Jr. R.T., Kam K., Qureshi T., Johnson J., Copenhagen D.R., Storm-Mathisen J., Chaudhry F.A., Nicoll R.A., and Edwards R.H. Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites. Science 304 (2004) 1815-1819
12. Fremeau Jr. R.T., Voglmaierm S., Seal R.P., and Edwards R.H. VGLUTs define subsets of excitatory neurons and suggest novel roles for glutamate. Trends in Neuroscience 27 (2004) 98-103
13. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. American Journal of Psychiatry 158 (2001) 1367-1377
14. Groenewegen H.J., and Berendse H.W. The specificity of the "non-specific" midline and intralaminar thalamic nuclei. Trends in Neuroscience 17 (1994) 52-57
15. Hartig W., Riedel A., Grosche J., Edwards R.H., Fremeau Jr. R.T., Harkany T., Brauer K., and Arendt T. Complementary distribution of vesicular glutamate transporters 1 and 2 in the nucleus accumbens of rat: relationship to calretinin-containing extrinsic innervation and calbindin-immunoreactive neurons. Journal Comparative Neurology 465 (2003) 1-10
16. Henderson J.M., Carpenter K., Cartwright H., and Halliday G.M. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain 123 (2000) 1410-1421
17. Herzog E., Bellenchi G.C., Gras C., Bernard V., Ravassard P., Bedet C., Gasnier B., Giros B., and El Mestikawy S. The existence of a second vesicular glutamate transporter specifies subpopulations of glutamatergic neurons. Journal of Neuroscience 21 (2001) RC181
18. Hirsch E.C., Perier C., Orieux G., Francois C., Feger J., Yelnik J., Vila M., Levy R., Tolosa E.S., Marin C., Trinidad Herrero M., Obeso J.A., and Agid Y. Metabolic effects of nigrostriatal denervation in basal ganglia. Trends in Neuroscience 23 (2000) S78-S85
19. Huang H., Ghosh P., and van den Pol A.N. Prefrontal cortex-projecting glutamatergic thalamic paraventricular nucleus-excited by hypocretin: a feed forward circuit that may enhance cognitive arousal. Journal of Neurophysiology 95 (2006) 1656-1668
20. Hur E.E., and Zaborszky L. Vglut2 afferents to the medial prefrontal and primary somatosensory cortices: a combined retrograde tracing in situ hybridization. Journal of Comparative Neurology 483 (2005) 351-373
21. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Molecular Psychiatry 9 (2004) 984-997
22. Kinomura S., Larsson J., Gulyas B., and Roland P.E. Activation by attention of the human reticular formation and thalamic intralaminar nuclei. Science 271 (1996) 512-515
23. Moechars D., Weston M.C., Leo S., Callaerts-Vegh Z., Goris I., Daneels G., Buist A., Cik M., van der Spek P., Kass S., Meert T., D'Hooge R., Rosenmund C., and Hampson R.M. Vesicular glutamate transporter VGLUT2 expression levels control quantal size and neuropathic pain. Journal of Neuroscience 26 (2006) 12055-12066
24. Moutsimilli L., Farley S., Dumas S., El Mestikawy S., Giros B., and Tzavara E.T. Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology 49 (2005) 890-900
25. Namima M., Sugihara K., Watanabe Y., Sasa H., Umekage T., and Okamoto K. Quantitative analysis of the effects of lithium on the reverse tolerance and the c-Fos expression induced by methamphetamine in mice. Brain Research Brain Research Protocols 4 (1999) 11-18
26. Ni B., Rosteck Jr. P.R., Nadi N.S., and Paul S.M. Cloning and expression of a cDNA encoding a brain-specific Na(C)-dependent inorganic phosphate cotransporter. Proceedings National Academy of Science of the United States of America 91 (1994) 5607-5611
27. Ong J.C., Brody S.A., Large C.H., and Geyer M.A. An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition. Journal of Pharmacology and Experimental Therapeutics 315 (2005) 1163-1171
28. Paxinos G. The Rat Nervous System (1995), Academic Press Inc. 629-686
29. Paxinos G., and Watson C. The Mouse Brain in Stereotaxic Coordinates (1997), Academic Press, New York
30. Perez-Manso M., Barroso-Chinea P., Aymerich M.S., and Lanciego J.L. 'Functional' neuroanatomical tract tracing: analysis of changes in gene expression of brain circuits of interest. Brain Research 1072 (2006) 91-98
31. Price J.L. Prefrontal cortical networks related to visceral function and mood. Annals NY Academy of Sciences 877 (1999) 383-396
32. Qiao H., Noda Y., Kamei H., Nagai T., Furukawa H., Miura H., Kayukawa Y., Ohta T., and Nabeshima T. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 12 (2001) 11-15
33. Rieck R.W., Ansari M.S., Whetsell Jr. W.O., Deutch A.Y., and Kessler R.M. Distribution of dopamine D2-like receptors in the human thalamus: autoradiographic and PET studies. Neuropsychopharmacology 29 (2004) 362-372
34. Robertson G.S., Lee C.J., Sridhar K., Nakabeppu Y., Cheng M., Wang Y.M., and Caron M.G. Clozapine-, but not haloperidol-, induced increases in deltaFosB-like immunoreactivity are completely blocked in the striatum of mice lacking D3 dopamine receptors. European Journal of Neuroscience 20 (2004) 3189-3194
35. Schambra U.B., Duncan G.E., Breese G.R., Fornaretto M.G., Caron M.G., and Fremeau Jr. R.T. Ontogeny of D1A and D2 dopamine receptor subtypes in rat brain using in situ hybridization and receptor binding. Neuroscience 62 (1994) 65-85
36. Smith R.E., Haroutunian V., Davis K.L., and Meador-Woodruff J.H. Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. Neuroreport 12 (2001) 2885-2887
37. Smith Y., Raju D.V., Pare J.F., and Sidibe M. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends in Neuroscience 27 (2004) 520-527
38. Svenningsson P., Tzavara E.T., Witkin J.M., Fienberg A.A., Nomikos G.G., and Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proceedings of the National Academy of Sciences USA 99 (2002) 3182-3187
39. Takamori S., Rhee J.S., Rosenmund C., and Jahn R. Identification of differentiation-associated brain-specific phosphate transporter as a second vesicular glutamate transporter (VGLUT2). Journal of Neuroscience 21 (2001) RC182
40. Tordera R.M., Pei Q., and Sharp T. Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment. Journal of Neurochemistry 94 (2005) 875-883
41. van Rijnsoever C., Tauber M., Choulli M.K., Keist R., Rudolph U., Mohler H., Fritschy J.M., and Crestani F. Requirement of alpha5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice. Journal of Neuroscience 24 (2004) 6785-6790
42. +/PI transporter as a novel vesicular glutamate transporter expressed in a distinct set of glutamatergic synapses. Journal of Neuroscience 22 (2002) 142-155
43. Wilson N.R., Kang J., Hueske E.V., Leung T., Varoqui H., Murnick J.G., Erickson J.D., and Liu G. Presynaptic regulation of quantal size by the vesicular glutamate transporter VGLUT1. Journal of Neuroscience 25 (2005) 6221-6234
44. Yamamoto B.K., and Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. Journal of Neuroscience 14 (1994) 4159-4166